Study says companies spend $100 million to promote blockbuster drugs

A study by Cutting Edge Information, Driving Successful Pharma Brands: Case Studies of Real Product Launches, said companies promoting blockbuster products routinely spend over $100 million on commercialization from Phase 3 through the first year that the product is publicly available. The study said Lilly will need an aggressive campaign for Prasugrel to compete with Bristol-Myers Squibb/Sanofi-Aventis's Plavix in Europe, where the delayed-in-the-US Lilly drug won approval. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions